News tagged with serious adverse events
High doses of saw palmetto appear safe over 18 months
(HealthDay)—Extracts of saw palmetto berry used at doses of up to 960 mg daily appear to be safe over an 18-month period, according to a study published in the April issue of The Journal of Urology.
Diseases, Conditions, Syndromes
Apr 29, 2013 |
5 / 5 (1) |
0
Reducing the pain of movement in intensive care
Monitoring pain and providing analgesics to patients in intensive care units (ICUs) during non-surgical procedures, such as turning and washing, can not only reduce the amount of pain but also reduce the number of serious ...
Other
Apr 17, 2013 |
not rated yet |
0
MS patients did not benefit from CCSVI intervention
The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation ...
Neuroscience
Mar 15, 2013 |
not rated yet |
0
|
Follow-up to REDUCE study shows low rate of prostate cancer diagnosis
The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged ...
Cancer
Jan 22, 2013 |
not rated yet |
0
Adalimumab relieves hidradenitis suppurativa
(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment ...
Inflammatory disorders
Dec 18, 2012 |
not rated yet |
0
AHA: Allogeneic stem cells OK in ischemic cardiomyopathy
(HealthDay)—For patients with ischemic cardiomyopathy (ICM), allogeneic bone marrow-derived mesenchymal stem cells (MSCs) are safe; and delivery of bone marrow mononuclear cells (BMC) to patients with ST-segment ...
Cardiology
Nov 07, 2012 |
not rated yet |
0
Immunosuppressant switch cuts skin cancer post-transplant
(HealthDay) -- In kidney-transplant patients with at least one cutaneous squamous-cell carcinoma, switching immunosuppressants (from calcineurin inhibitors to sirolimus) is associated with increased skin cancer-free ...
Cancer
Jul 26, 2012 |
not rated yet |
0
Supplement mixture improves memory in mild Alzheimer's
(HealthDay) -- A supplement mixture (Souvenaid) containing dietary precursors and specific nutrients can improve memory in drug-naive patients with mild Alzheimer's disease (AD), according to a study published ...
Alzheimer's disease & dementia
Jul 12, 2012 |
4 / 5 (3) |
1
|
Phase I study of temsirolimus, capecitabine proves safe; positive survival trend seen
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive ...
Cancer
May 16, 2012 |
5 / 5 (1) |
0
Albendazole cuts enteric parasite prevalence in refugees
(HealthDay) -- The administration of a single 600-mg dose of albendazole to United States-bound refugees prior to departure from Africa and Southeast Asia reduces the prevalence of intestinal nematodes, according ...
Health
Apr 19, 2012 |
not rated yet |
0
Cytori breast reconstruction cell therapy trial results published
Cytori Therapeutics announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.
Cancer
Mar 19, 2012 |
not rated yet |
0
Misoprostol substantially reduces serious complications in early termination of pregnancy
Cervical preparation with misoprostol reduces major complications of early surgical abortion by almost a third compared with placebo, according to new research published Online First in The Lancet.
Obstetrics & gynaecology
Mar 07, 2012 |
not rated yet |
0
First US embryonic stem cell trial is halted
The first-ever trial using human embryonic stem cells to treat paralysis has been halted due to high costs and the company will focus instead on new cancer treatments, Geron said Tuesday.
Medical research
Nov 15, 2011 |
2.5 / 5 (4) |
2
Commonly used 3-drug regimen for idiopathic pulmonary fibrosis found harmful
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic ...
Diseases, Conditions, Syndromes
Oct 21, 2011 |
not rated yet |
0
Benefits of radionuclide therapy for neuroendocrine tumors
According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate) , is effective not only i ...
Cancer
Sep 20, 2011 |
5 / 5 (2) |
1
